The results of our investigation caused MERCK Company in early 1975 to remove the stabilizer from the 10 mg ampules of Refobacin®. We have tested primarily Refobacin® 10 mg ampules from the production of 1973/74 and those from 1975 in comparison, later on:
l Methods
Homozygous Gunn rats, 3-5 days and one month old respectively, served äs experimental animals. As genetically determined inborn error of metabolism they lack glucuronyj transferase. They cannot couple bilirubin to glucu-* S upported by Deutsche Forschungsgemeinschaft (Ha 534/5) ronic acid and suffer from a life-long hyperbilirubinemia and they usually develop a mfld to moderate kernicterus during the first two weeks of life. Its extent can be determined histochemically in the PURKINJE' cells of the cerebellum. Tab. I tabulates the preparations tested and the substances contained in the stabilizers äs communicated to us by the manufacturers. In addition to the commercial preparations we investigated the stabilizers of the 40 mg Refobacin and the 10 and 40 mg Sulmycin® ampules alone äs well äs the separate ingredients of the stabilizers benzyl alcohol and di-Na-EDTA. In a pilot study, we determined in heterozygous (non icteric) young Gunn rats, the LD 50, i. e. the acute toxicity of the several preparations according to the method of BEHRENS and KÄRBER. The results were calculated from the survival rate four days after the injection.
Experimental Series l contained 3-5 day old homozygous animals who received a single high dose (50-75% of the LD 50 for heterozygous animals) of the particular test preparation subcutaneously. Prior to the injection, and 30 minutes, 3 hours, 24 hours, and in some instances 48 hours after the injection, the serum bilirubin concentration was determined in blood from the tau (direct photometric method with American Optical Bilirubinometer).
In order not to stress the neonatal rats too much by frequent blood drawings the neonatal rats were tested usually only three times. In all animals the first sample was obtained before the injection, the second sample was obtained in some animals after thirty minutes and others after three hours and the third sample in most animals after 24 hours with several at 48 hours. The graphic illustrations equate the pre-injection value with 100 and deTab. I.
Tested preparations

Contents
Additives in ampules according to manufacper ampule turers* Information per ml
A. GENTAMICIN Refobacin® X 40 mg Garamycin® (diagnostic reagent, pure substance) 3 B. Other AMINOGLYCOSIDES 1 ml Na-pyrosulfite di-Na-EDTA benzyl alcohol 2 ml di-Na-EDTA NaCl benzyl alcohol 2 ml none l ml none l ml methylparaben The first example is the lyophilized preparation Refobacin® L 5 mg without stabilizer for intrathecal use ( 400 mg/kg of gentamicin from Refobacin® 40mg, ampules ( Fig. 2) caused a more pronounced drop in serum bilirubin, lasting longer than three hours. The decrease is even more pronounced with the higher dose. As little äs 50 mg/kg Refobacin® from 10 mg ampules manufactured in 1973/74 (Fig. 3 ) caused a drop in serum bilirubin similar in magnitude to that seen with 400 mg/kg from 40 mg ampules. This allows the assumption that the responsible factor is the associated injection of stabilizer in an amount of 0.01 ml/g. The serum bilirubin is lowered even more by 100 and 200 mg/kg from 10 mg ampules (1973/74 production), lasting for over 24 hours. Very similar curves are generated if STAB Refo 40 without antibiotic (Fig. 4) or only benzyl alcohol (Fig. 5 ) "äre adminstered. Fig. 6 demonstrates graphically the lines corresponding to 0.04 ml/g from the three preceeding illustrations. The bilirubin decrease coincides so well that the conclusion is justified that benzyl alcohol is the solely responsible agent. After injection of 200 and 400 mg/kg gentamicin from the new Refobacin® 10 mg ampules (1975 production) a similar influence on the serum bilirubin concentration is not seen (Fig. 7) . Curves obtained after gentamicin injections from Sulmycin® ampules (Fig. 8) äs well äs those after injection of stabilizers without the antibiotic (Fig. 10) indicate only a low bilirubin displacement. A clear dose related effect from the methyl and propyl-paraben in the stabilizers is not demonstratable. Pure gentamicin (äs the diagnostic reagent of SCHERING Corporation, Garamycin®) was tested in addition to the 200 and 400 mg/kg doses also in the amount of 5 mg/kg used in clinical practice.
No indications for a displacement of bilirubin from plasma protein were found. The curves for kanamycin (Fig. 13) , tobramycin (Fig. 9) , and sisomicin ( Fig. 11 and 12 ) do not indicate bilirubin displacement. Di-Na-EDTA was tested äs a single stabilizer substance;it döes not influence the bilirubin concentration.
Administration of single high doses to 3-4 week old homozygous Gunn rats
In experimental series 2, three to four week old homozygous Gunn rats received 100 to 400 mg/kg gentamicin from Refobacin® L 5 mg ampules, 5 and 400 mg/kg from böth Sulmycin® ampules äs well äs 5 and 100 to 400 mg/kg pure substance (Garamycin®). As in 3 to 5 day old animals there was no influence on the serum bilirubin concentration. In comparison with the young rats ( Fig. 2 and 3 ) the primary bilirubin decrease is steeper, the return to the original values is quicker, and higher doses are tolerated. The difference in the return of the bilirubin concentration indicates probably a different metabolic rate for benzyl alcohol in the two age groups because of the postnatal development öf enzyme Systems [31] . In order to explain the differences in the slope of the initial decrease, one coüld postulate for the younger animals either a decreased resorption or it could be assumed that the effect is not caused by the benzyl alcohol but by its metabolites. 
Repeated injections in low doses to young hemozygous rats
Tab. III summarizes the survival of rats (3-5 days old at the beginning of the experiment) after one injection of gentamicin and after several injections repeated at 24 hour intervals (experimental series 3) from the three tested ampules for use in infants.
The high mortality after one 200 mg/kg injection and five 100 mg/kg injections from Refobacin® 10 mg ampules (1973/74 production) is clearly evident. On the other hand, 21 of 24 animals survived who had received ten injections of 50 mg/kg of this preparation. The last column lists the mean weight gain for all animals who received ten injections if their base line weight was at least 9 grams. Here, too, Refobacin® 10 mg (1973/74 production) compares unfavorably with the other preparations. Tab. IV summarizes findings in regard to the number of damaged PURKINJE' cells in the cerebellum of the animals. Ten to eleven days after the experiment when the rats were 13-16 days old the extent of the loss of PURKINJE' cells (PCL) in the vermis of the cerebellum has been estimated ( Fig. 16-18 ). If animals who have had an increased PCL and those who died during the experimental period are added and compared to those with the amount of PCL expected for the age, the detrimental fact of Refobacin® 10 mg (1973Π'4 production) is quite evident. The dose of 100 mg/ kg is not different in regard to the occurrence of kernicterus between l (not indicated in Tab. III) 2, and 5 doses; however, with 50 mg/kg a difference can be seen when 5 and 10 injections are compared. After ten 5 mg/kg Refobacin® 10 mg (1973/74 production) injections the adverse effect cannot be recognized. The extent of the damage to the ganglion cells after this low dose cannot safely be distinguished from that in animals who received normal saline solution or the other two gentamicin preparations in high doses.
Discussion
The various methods of determining displacement of bilirubin from albumin by drugs were compared by YEARY and DAVIS in 1974 [32] . Among the in vitro methods the separate sephadex-gel-filtration of proteinbound and unbound (so-called free) bilirubin proved particularly useful. Results obtained with this method corresponded well with the observed decrease in serum bilirubin concentration of icteric Gunn rats. The authors ascribe high potential for the testing of new drugs intended for use in the perinatal period to in vivo in- The risk of kernicterus from sulfonamides was identified first by clinicians through a careful controlled study in prematures. The animal model at that time helped to clarify the pathogenetic mechanism. The degradation of benzyl alcohol, benzoic acid and its derivatives is similar in man and rat. It leads to the formation of hippuric acid which is excreted in the urine. It may be expected that effects caused by these substances in rats may also occur in the human. We began our drug studies in Gunn rats in 1973 primarily to verify the protective effect of phototherapy for kernicterus. We wanted to test wheth- er the provocation of kernicterus by drugs may be prevented by simultaneous phototherapy and this question was soon answered in the affirmative. During the selection of substances which displace bilirubin from albumin and thus enhance the occurrence of kernicterus, we encountered gentamicin. When we began to use this antibiotic we were unaware of the differences in the preparations of the various commercial bränds. In GERMANY additives do not have to be listed. Initially we used
Refobacin^ 10 mg and Refobacin 40 mg ämpu-les without particular preference according to the supply. Only after we recognized the marked difference in the acute toxicity and the different influence on the serum bilirubin concentration did we ask the manufacturer about the different additives in the ampules. From the work of BRATLID and LANGSLET [5] it was then known that ampules of diazepam of different origin do not displace bilirubin equally from the albumin bond. STERN and SCHIFF [27, 22] demonstrated that the bilirubin displacement from injectable Valium was not caused by the diazepam, but by the benzoate in the stabilizer. They demonstrated a similar effect of the benzoate component in caffeine sodium benzoate. Thus, it appeared reasonable to investigate in particular the benzyl alcohol in the stabilizer of Refobacin and the paraoxybenzoic acid ester in the stabilizers of Sulmicin® and the other tested aminoglycosides. The molecular weight of benzyl alcohol is 108, that of methylparaben 152, and of propylparaben 180. If it is assumed that the portion of the molecules responsible for protein binding is situated on the phenol ring the effect of parabene should be estimated äs at least 1/3 less than that of benzyl alcohol. In a comparison of the ratio of the amounts of benzyl alcohol and benzoic acid ester (Tab. V) to that of the active ingredient it is evident that all ampules for use in infants contain more of them than the adult dosage form. This fact makes a general review of Solutions for pediatric injections highly advisable. Furthermore, it is apparent that the amount of critical additives in Refobacin® 10 mg ampules (1973/74 production) is markedly higher than in all other preparations. It is by weight twice äs high LD 50 of Sulmycin 40 mg and Sulmycin1 0mg ampules (Tab. II) can probably also be related to the stabilizer addition. In order to evaluate the noticably lesser difference in the LD 50 of Refobacin® 40 mg, Refobacin® 10 mg (1975 production) and Refobacin® L 5 mg as well as sisomicin 75 mg and Sisomicin 20 mg the findings must be corroborated with considerably larger numbers of experimental animals. This is an Obligation of the manufacturers. Because of the considerable difference in the various ampules we think it imparative that the package inserts do not only list the LD 50 of the drug as a pure substance, but also that of the specific preparation. A further question is that of the relation between doses which damage Gunn rats and those in clinical use. Before the recognition of the bilirubin displacement, newborns received daily doses of 100 to 200 mg/kg of sulfisoxazol (Gantrisin®). A one time injection of these doses causes a decrease in bilirubin to about 50% of the base line value for longer than three hours in Gunn rats. An increased PCL can be demonstrated after only one injection of 100 mg/kg. After 400 mg/kg the bilirubin displacement persists for more than 24 hours. A de* creased weight loss is recognizäble after l X 600 mg/kg and an increased mortality after l X 800 mg/kg (i. e. 4 to 8 times the usual daüy dose). Only few animals survive 1000 mg/kg. NATHENSON and co-workers [17] studied thebilirubinlowering effect of sodium benzoate in Gunn rats in regard to the risk of the stabilizer in Valium® for newborns. They were able to demonstrate a decrease in serum bilirubin above that seen with NaCl injections only after several intraperitoneal injections of 35 mg/kg of sodium benzoate. This corresponds to about 3 mg/kg of Valium®, a high dose which is used in the treatment of neonatal seizures. However, the authors considered only the sodium benzoate in the Valium stabilizer and disregarded the also present 10mg benzyl alcohoi. Only after 200 mg/kg sodium benzoate the bilirubin decrease resembled that seen with 200 mg/kg sulfisoxazol. In our laboratory we tested in early experiments (l, 26) the complete Valium stabilizer (without the active ingredient) in 3-5 day old rats. After subcutaneous injection of an amount containing 170 mg/kg sodium benzoate plus 50 mg/kg benzyl alcohoi (in addition to propylen glycol and ethyl alcohoi), the decrease in bilirubin corresponded to that after 200 mg/kg benzyl alcohoi. NATHENSON et al. [17] concluded from their results that injectable Valium did not constitute a danger for newborns in regard to bilirubin displacement from albumin binding, especially considering the higher binding capacity of human albumin, as long as recommended doses were not grossly exceeded. Newborns receive 3-5 mg/kg gentamicin per day and in sepsis up to 8 mg/kg. After treating young Gunn rats for ten days with daily doses of 5 mg/kg Refobacin® 10 mg (1973/74 production) we found no certain evidence of increased PCL. One injection of 50 mg/kg caused a bilirubin drop for longer than three hours to about 80 % of the original value. Animals receiving 50 mg/kg daily for ten days showed an increase PCL and the weight gain was reduced. After 100 mg/kg serum bilirubin remained decreased for over 24 hours to 65 % to 75 % of Ihc basc line value and thc mortality was markedly incrcased (with a 10-20 times the clini· cal dose). Only one of 26 animals survived one injection of 200 mg/kg. U may be concluded that in ncwborns with a physiological level of albumin, and only moderate ictcrus the administration of Rcfobacin® from thc 10 mg ampules (produced in 1973/74) alone in a moderate dose did not stress the albumin rcscrve binding capacity disconcertingly. However, with the co-occurrence of several important factors such äs pronounced hypoalbuminemia, acidosis, decreased rena) function, and Ihe administration or endogenous accumulation of substances competing for protcin binding, one cannot exclude competitive displacement of bilirubin and thus a neuronal damagc by a superfluous additive. In comparison to Refobacin® lOmg/ampules (1973/74 production) the demonstrable effectsof stabilizers in all other tested commercial preparations are minimal. The question whether they are indeed necessary for the preparation and stabilization of aminoglycoside Solutions will not be discussed herc. The fact that in Germany, additives in Solutions or injections do not have to be declared cvcn if their amount is higher than that of the active ingredient is higlily unsatisfactoiy. Every pediatrician who is in a position to Order drugs for icteric newborns and prematures would appreciate the possibility to calculate at least the total amount of benzoic acid derivatives which the child receives in one day. Wc have not found in our experiments any indica-(ions for displacement of bilirubin by aminoglycosides. Possibly, the varying data in the literature may be explained in part by the various additives of stabilizers. Howcver, we cannot prove this because not all publications list the specific commercial preparations under study. A comparison of the change in serum bilirubin content after Refobacin® 10mg (1973/74 production) and benzyl alcohol in 3-5 day old and 3-4 week old homozygote Gunn rats has biological and clinical interests in regard to the so-called maturation of metabolic functions and should cause a further standarization of the animal model used. Neither in newborn humans [28] nor in young rats [4] the degradation of benzoate to ! hippurate occurs with the same speed seen in older individuals. Also the hippuric acid excretion by the kidney is decreased in the neonate of both species [10, 14, 21] .
j, DAvis and YEARY [7] studied in two day old and ' in adult homozygous Gunn rats the fate of labeiled bilirubin after displacement from the plasma-albumin bond by sulfadimethoxin. The percent distribution in the different tissues varied between young and old animals. Adult animals had a marked accumulation in the liver while in young animals it appeared in the gastro-intestinal tract (a probable explanation is the lack of and Z proteins in the liver of the young animals). In both adult and newborn rats the dye appeared in the brain. Only in young rats was there a marked difference in the LD 50 of sulfadimethoxin between homozygous (icteric) and heterozygous (nonicteric) rats -63 mg/kg versus 770 mg/kg. The jauthors concluded a higher sensivity for the toxic action of free bilirubin, in the young animals. In testing drugs on Gunn rats one has to expect different results between adult and young animals of varying ages. It is not clear which age group: 2, 5, or even 10 days old rats represent best the conditions in newborn and premature infants (see 8).
Summary Thc cffcct of scvcral antibiotics of aminoglycoside structurc on the albumin binding of büirubin has been tested in homozygous (jaundiccd) Gunn rats aged 3-5 days. The following drugs were invcstigatcd: different preparations of gcntamycin, kanamycin, tobramycin and sisomicin. Thc animals rccoivcd 50-75 % of tjie LD 50 of heterozygous (non-jaundiced) Gunn rats. Mortality, wcight gain and changcs in the plasma büirubin concentration werc rccordcd.
It was found that the displacement of bilirubin from albumin is caused by the different stabilizers used and not by the antibiotic itself. With the exception of lyophilized preparations of gentamycin for intrathecal application all vials contain different amounts of thesc preservatives. Special preparations used during the newborn period contain relatively more of these stabilizers. The toxicity of the additives has already a negative influence on the LD 50 for heterozygous Gunn rats when Ballowitz et al" Aminogiycoside preparations On a pu prouver que le$ antibiotiques meines ne «deplac» dient» pas la biliruhine liee aux aJbumineg du sarum. En dehors des ampoules prevues pour Tappliaation in* trathocale et dans lesquelles l'antibiotique se trouve sous forme iyophllisee, (es autres proparations commerciales conliennent des quantitees differentes d'additifs ou stabilisateurs, II est interessant de relever que, bien que renfcrmant des doses relativement faibles d'antibiotique, le.s pmpoules prevues pour les pourrissons contiennent davantage de ces matieres stabilisatrices que les ampoules reservees aux adultes, Meme chez les animaux heterozygotes, la letalite (LDso) est infiuencee par les stabilisatours dans les ampoules a dose minime de Refobacine®et Sulmycine® La tolerance de la Refobacine® ä 10 mg (production 1973/74) est presque reduite de moitie, Chez les animaux homozygotes, la toxicite causee par le stabilisateur de la Refobacine®a 10 mg (production 1973/74) est eneore plus marquantß. a ete etabli que chez le rat ieterique, l'alcool benzylique, contenu dans ce stabilisateur, deplace la bilirubine fixee a raibumine. La eoncentration de la bilirwbinö du serum baisse paialJelement a la dose injectoe pour plus de 3 ou pour plus de 24 heures. De cette maniere, onpcut mesurer d'une fagon relativement simple et preise le doplaccmcnt eompetitif de la büirubine, La bilirubine non Hee renforce par sä neurotoxicite Kictere nucleaire, ce qui a pu ctrc domontro clairement chez des jeunes rats homozygotes ayant re<^u plusicurs doses plus faibles* Diverses reactions histochimiques pour lactatdohydrogenaseet NADH2;tetrazoliumreductase ont permis de demontrer une deterioration importante des cellules de PURKINJE du cervclet. Les stabilisateurs de toutes les autres preparations sont relativement insignifiants. Enfin on a compare la duree et la vitesse de la baisse du taux de bilirubine apres injection de certains stabilisateurs juges critiques chez dos rats Gunn icteriqucs ages de 3 ä 4 semaines et de 3 ä 5 jours, Les differences constatecs somblent s'expliquer par le metabolisme accelere des benzoates chez les animaux plus ages, On n'a toujours pas resolu la question quol est Tage des rats Gunn qui redete le mieux la Situation chez les enfants nouveaux-nes ou prematures, Mots cles: Rats Gunn, medicaments (la liaison bilirubine/albumine), hyperbilirubinemie des nouveauxnes.
Durjng the timeof editing we tested one more aminoglycosJd i, e. Amikacln (Biklin® Grünenthal/Biistol), Using the 100 mg vials (for babies) s^rumbilirubin did not decrease at all after an Injection of 500 mg/kg. When 1000 mg/kg were given, a rather small deciease (about 10% of the starting level) could be noticed. The manufactiuers inforrned us that neither the stabilizers of the formulation for babies not for adults contain benzoates or benzylalcohd. 
